Literature DB >> 19202328

KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004.

Jon J Snyder1, Allan J Collins.   

Abstract

BACKGROUND/AIMS: National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines aim to slow chronic kidney disease (CKD) progression and reduce morbidity and mortality. This study aimed to assess current CKD population health and adherence to recommendations in National Health and Nutrition Examination Survey 1999-2004 participants aged >or=20 years (n = 14,213).
METHODS: We assessed hypertension and dyslipidemia management and diabetes control, stratified by CKD status and prior history of cardiovascular disease (CVD), to ascertain awareness, treatment, and control.
RESULTS: Hypertension was likelier among participants with than without CKD regardless of CVD history, but awareness, treatment, and control were not. Hypertensive participants with CKD were less likely than those without to be taking angiotensin-converting enzyme inhibitors or angiotensin receptor-blocking agents. Of participants with no CVD history, high cholesterol was likelier among those with CKD stages 3-4 than among those without CDK, but awareness and treatment were less likely; of participants with CVD history, high cholesterol was less likely among those with than without CKD, and awareness and treatment were as likely. Diabetes control was less likely among diabetic participants with early-stage CKD than without CKD, but not significantly different between late-stage and non-CKD participants.
CONCLUSIONS: The study timeframe coincided with or pre-dated release of KDOQI guidelines. Many opportunities for improvement in CKD patient care are evident. Future releases of NHANES data could be used to assess whether improvement occurs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19202328     DOI: 10.1159/000201014

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  16 in total

1.  Primary care management of chronic kidney disease.

Authors:  Adrienne S Allen; John P Forman; E John Orav; David W Bates; Bradley M Denker; Thomas D Sequist
Journal:  J Gen Intern Med       Date:  2010-10-05       Impact factor: 5.128

Review 2.  Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 3.  Hypertension and kidney disease: what do the data really show?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

4.  Neuropeptide Y levels are associated with nutritional status and cardiovascular events in adults with chronic kidney disease.

Authors:  L Lu; Y-C Zou; M Wang; Y-F Huang; D-X Chen; L-B Wei
Journal:  Eur J Clin Nutr       Date:  2015-04-29       Impact factor: 4.016

5.  The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study.

Authors:  David K Hooper; Jason C Williams; Adam C Carle; Sandra Amaral; Deepa H Chand; Maria E Ferris; Hiren P Patel; Christoph Licht; Gina-Marie Barletta; Veronica Zitterman; Mark Mitsnefes; Uptal D Patel
Journal:  Pediatr Nephrol       Date:  2013-02-17       Impact factor: 3.714

6.  Analysis of the Clinical Characteristics of Patients with Acute Coronary Syndrome in Different States of Renal Function.

Authors:  L-H Hu; L-J Zhang; Z-T Jin; W Yang; L-N Zhang; C-Y Lu
Journal:  West Indian Med J       Date:  2015-05-06       Impact factor: 0.171

7.  Learning from marketing: Rapid development of medication messages that engage patients.

Authors:  Veronica Yank; Erika Tribett; Lydia Green; Jasmine Pettis
Journal:  Patient Educ Couns       Date:  2015-03-14

8.  Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease.

Authors:  Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Eric J MacLaughlin; James Hoehns; Oralia V Bazaldua; Timothy J Ives; David L Hahn; Christopher S Coffey; Barry L Carter
Journal:  Pharmacotherapy       Date:  2018-02-23       Impact factor: 4.705

9.  Are the recommended blood pressure goals in high-risk patients based on outcome data or opinion?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-20       Impact factor: 3.738

10.  Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States.

Authors:  Chris LaVallee; Karen L Rascati; Tyler H Gums
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-20       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.